Inhaled Ebola vaccine shows promise

An inhalable vaccine to protect against Ebola has shown promise in trials involving non-human primates, and will start being tested soon on humans, according to a report in the journal Molecular Phamaceutics.

Researchers gave the animals the vaccine in an inhalable form and found it dramatically improved survival rates for primates infected with the Ebola strain that's killed thousands of people in West Africa. The vaccine was fully protective 21 weeks after immunization.

However, when the animals were given the vaccine as an injection, only half survived. Maria Croyle, co-author of the study, noted that the advantage of the inhalable vaccine  was that a single dose provided long lasting protection and could be more safely implemented in locations with weak health infrastructures, as compared to injectable vaccines.

Currently, 70 percent of the people who have contracted the virus in West Africa have died.

NEXT: High triglycerides raise risk of prostate cancer recurrence

Sourced from: Medical News Today , Lasting protection against Ebola from single-dose inhaled vaccine looks feasible